Publication:
Absolute PSA value after androgen deprivation (AD) is a strong independent predictor of survival in new metastatic (D2) prostate cancer (PCa): Data from Southwest Oncology Group Trial 9346 (INT-0162).

Simple item page
dc.contributor.authorsHussain, M.; Tangen, C. M.; Schellhammer, P. F.; Crawford, E. D.; Higano, C. S.; Wilding, G.; Akdas, A.; Small, E. J.; Donnelly, B.; Raghavan, D.
dc.date.accessioned2022-03-12T15:59:41Z
dc.date.accessioned2026-01-11T17:23:30Z
dc.date.available2022-03-12T15:59:41Z
dc.date.issued2006
dc.identifier.doidoiWOS:000239009401318
dc.identifier.issn0732-183X
dc.identifier.urihttps://hdl.handle.net/11424/224480
dc.identifier.wosWOS:000239009401318
dc.language.isoeng
dc.publisherAMER SOC CLINICAL ONCOLOGY
dc.relation.ispartofJOURNAL OF CLINICAL ONCOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.titleAbsolute PSA value after androgen deprivation (AD) is a strong independent predictor of survival in new metastatic (D2) prostate cancer (PCa): Data from Southwest Oncology Group Trial 9346 (INT-0162).
dc.typeconferenceObject
dspace.entity.typePublication
oaire.citation.endPage221S
oaire.citation.issue18
oaire.citation.startPage221S
oaire.citation.titleJOURNAL OF CLINICAL ONCOLOGY
oaire.citation.volume24

Files

Collections

Araştırma Çıktıları